Novartis
Leqvio
page 3 of 4
4C
IMPORTANT SAFETY INFORMATION (continued)
Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with 
LEQVIO. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to seek medical attention promptly. 
Adverse Reactions: Adverse reactions in clinical trials (≥3% of adult patients treated with LEQVIO and more frequently than placebo) were 
injection site reaction, arthralgia, and bronchitis.
References: 1. Niu X, Popadic L, Xinshuo M, et al. Treatment patterns among early inclisiran vs anti-PCSK9 mAbs users: a retrospective analysis of US claims databases. 
Poster presented at: National Lipid Association Scientific Sessions 2024; May 30-June 2, 2024; Las Vegas, NV. 2. Leqvio. Prescribing information. Novartis Pharmaceuticals 
Corp. 3. Data on file. ORION-10. Novartis Pharmaceuticals Corp; 2025. 4. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of 
inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519.
Please see additional Important Safety Information on the previous page and Brief Summary of Prescribing Information 
on adjacent page.
Licensed from Alnylam Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 
© 2026 Novartis 
Printed in USA 
4/26 
FA-11661526

View this content as a flipbook by clicking here.